BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 205 filers reported holding BRIDGEBIO PHARMA INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $349,349 | +77.3% | 20,311 | +2.4% | 0.04% | +140.0% |
| Q3 2022 | $197,000 | +13.9% | 19,834 | +3.8% | 0.02% | +7.1% |
| Q2 2022 | $173,000 | -87.9% | 19,104 | -86.5% | 0.01% | -88.3% |
| Q1 2022 | $1,433,000 | +382.5% | 141,198 | +693.8% | 0.12% | +361.5% |
| Q4 2021 | $297,000 | +4.6% | 17,788 | +346.1% | 0.03% | -70.8% |
| Q4 2020 | $284,000 | – | 3,987 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |